News
Seagen and Astellas announce results from EV-302 study
The study involves Padcev – also known as enfortumab vedotin-ejfv – in combination with Keytruda (pembrolizumab) versus chemotherapy.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
The study involves Padcev – also known as enfortumab vedotin-ejfv – in combination with Keytruda (pembrolizumab) versus chemotherapy.